These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33307492)

  • 1. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
    Gerratana L; Davis AA; Polano M; Zhang Q; Shah AN; Lin C; Basile D; Toffoli G; Wehbe F; Puglisi F; Behdad A; Platanias LC; Gradishar WJ; Cristofanilli M
    Eur J Cancer; 2021 Jan; 143():147-157. PubMed ID: 33307492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.
    Rossi G; Mu Z; Rademaker AW; Austin LK; Strickland KS; Costa RLB; Nagy RJ; Zagonel V; Taxter TJ; Behdad A; Wehbe FH; Platanias LC; Gradishar WJ; Cristofanilli M
    Clin Cancer Res; 2018 Feb; 24(3):560-568. PubMed ID: 29180605
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
    Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
    Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
    Pestrin M; Salvianti F; Galardi F; De Luca F; Turner N; Malorni L; Pazzagli M; Di Leo A; Pinzani P
    Mol Oncol; 2015 Apr; 9(4):749-57. PubMed ID: 25539732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
    Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
    Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
    Ye Z; Wang C; Wan S; Mu Z; Zhang Z; Abu-Khalaf MM; Fellin FM; Silver DP; Neupane M; Jaslow RJ; Bhattacharya S; Tsangaris TN; Chervoneva I; Berger A; Austin L; Palazzo JP; Myers RE; Pancholy N; Toorkey D; Yao K; Krall M; Li X; Chen X; Fu X; Xing J; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
    Eur J Cancer; 2019 Jan; 106():133-143. PubMed ID: 30528798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients.
    Muendlein A; Geiger K; Gaenger S; Dechow T; Nonnenbroich C; Leiherer A; Drexel H; Gaumann A; Jagla W; Winder T; Mayer F; Decker T
    Sci Rep; 2021 Mar; 11(1):6761. PubMed ID: 33762647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
    Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA
    Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
    Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
    Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.
    Mentis AA; Grivas PD; Dardiotis E; Romas NA; Papavassiliou AG
    Cell Mol Life Sci; 2020 Sep; 77(18):3671-3690. PubMed ID: 32333084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Activating Estrogen Receptor Gene (
    Paolillo C; Mu Z; Rossi G; Schiewer MJ; Nguyen T; Austin L; Capoluongo E; Knudsen K; Cristofanilli M; Fortina P
    Clin Cancer Res; 2017 Oct; 23(20):6086-6093. PubMed ID: 28679775
    [No Abstract]   [Full Text] [Related]  

  • 17. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
    Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
    Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer.
    Keup C; Suryaprakash V; Hauch S; Storbeck M; Hahn P; Sprenger-Haussels M; Kolberg HC; Tewes M; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Genome Med; 2021 May; 13(1):85. PubMed ID: 34001236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape of circulating tumour DNA in metastatic breast cancer.
    Davis AA; Jacob S; Gerratana L; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Cristofanilli M
    EBioMedicine; 2020 Aug; 58():102914. PubMed ID: 32707446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.